Five-Year Longitudinal Assessment (2008 to 2012) of E-101 Solution Activity against Clinical Target and Antimicrobial-Resistant Pathogens

被引：1

作者：

Denys, Gerald A. ^{[1
]}

Pillar, Chris M. ^{[2
]}

Sahm, Daniel F. ^{[2
]}

O'Hanley, Peter ^{[3
]}

Stephens, Jackson T., Jr. ^{[3
]}

机构：

[1] Indiana Univ Sch Med, Indianapolis, IN 46202 USA

[2] Eurofins Medinet, Chantilly, VA USA

[3] Exoxemis Inc, Little Rock, AR USA

来源：

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2014年 / 58卷 / 08期

关键词：

NO ESKAPE; IN-VITRO; MYELOPEROXIDASE; BACTERIA; BINDING;

D O I：

10.1128/AAC.03020-14

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

This study summarizes the topical E-101 solution susceptibility testing results for 760 Gram-positive and Gram-negative target pathogens collected from 75 U.S. sites between 2008 and 2012 and 103 ESKAPE pathogens. E-101 solution maintained potent activity against all bacterial species studied for each year tested, with MICs ranging from <0.008 to 0.25 mu g porcine myeloperoxidase (pMPO)/ml. These results confirm that E-101 solution retains its potent broad-spectrum activity against U.S. clinical isolates and organisms with challenging resistance phenotypes.

引用

页码：4911 / 4914

页数：4

共 18 条

[11] Physiological production of singlet molecular oxygen in the myeloperoxidase-H2O2-chloride system
Kiryu, C
Makiuchi, M
Miyazaki, J
Fujinaga, T
Kakinuma, K
[J]. FEBS LETTERS, 1999, 443 (02) : 154 - 158
[12] Detection of β-lactamase-mediated resistance
Livermore, DM
Brown, DFJ
[J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2001, 48 : 59 - 64
[13] Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance
Magiorakos, A. -P.
Srinivasan, A.
Carey, R. B.
Carmeli, Y.
Falagas, M. E.
Giske, C. G.
Harbarth, S.
Hindler, J. F.
Kahlmeter, G.
Olsson-Liljequist, B.
Paterson, D. L.
Rice, L. B.
Stelling, J.
Struelens, M. J.
Vatopoulos, A.
Weber, J. T.
Monnet, D. L.
[J]. CLINICAL MICROBIOLOGY AND INFECTION, 2012, 18 (03) : 268 - 281
[14] ROLE OF HIGH-AVIDITY BINDING OF HUMAN NEUTROPHIL MYELOPEROXIDASE IN THE KILLING OF ACTINOBACILLUS-ACTINOMYCETEMCOMITANS
MIYASAKI, KT
ZAMBON, JJ
JONES, CA
WILSON, ME
[J]. INFECTION AND IMMUNITY, 1987, 55 (05) : 1029 - 1036
[15] Pendleton JN, 2013, EXPERT REV ANTI-INFE, V11, P297, DOI [10.1586/ERI.13.12, 10.1586/eri.13.12]
[16] Federal funding for the study of antimicrobial resistance in nosocomial pathogens: No ESKAPE
Rice, Louis B.
[J]. JOURNAL OF INFECTIOUS DISEASES, 2008, 197 (08) : 1079 - 1081
[17] ENHANCED KILLING OF MYELOPEROXIDASE-COATED BACTERIA IN MYELOPEROXIDASE-H2O2-CL-SYSTEM
SELVARAJ, RJ
ZGLICZYNSKI, JM
PAUL, BB
SBARRA, AJ
[J]. JOURNAL OF INFECTIOUS DISEASES, 1978, 137 (04) : 481 - 485
[18] The pig as a model for human wound healing
Sullivan, TP
Eaglstein, WH
Davis, SC
Mertz, P
[J]. WOUND REPAIR AND REGENERATION, 2001, 9 (02) : 66 - 76

← 1 2 →